Efficacy and Safety of the Angiotensin Receptor Blocker Valsartan in Children With Hypertension Aged 1 to 5 Years
Authors:
- 1 August 2008
- journal article
- research article
- Published by Wolters Kluwer Health in Hypertension
- Vol. 52 (2) , 222-228
Abstract
The efficacy and safety of valsartan were studied in 90 children (mean age: 3.2 years; 60% male; 30% black) with systolic blood pressure (SBP) ≥95th percentile. Nineteen percent received valsartan in addition to previous antihypertensive therapy. Subjects were randomly assigned to low-, medium-, or high-dose valsartan for 2 weeks (phase 1) and then reassigned randomly to placebo or to remain on the same valsartan dose for 2 additional weeks (phase 2). After this, subjects were enrolled into a 52-week, open-label phase during which valsartan was dosed to achieve SBP <95th percentile. Statistically significant reductions in SBP and diastolic blood pressure of ≈8.5 mm Hg and 5.7 mm Hg, respectively, were observed at the end of phase 1 in all of the valsartan dose groups. SBP and diastolic blood pressure were also significantly lower during phase 2 in valsartan recipients compared with placebo recipients. SBP <95th percentile was achieved in 77.3% of subjects during the open-label phase. Adverse events were minor and occurred at similar frequencies in each of the 3 dose groups in phase 1 and at equal frequencies in the valsartan and placebo arms in phase 2. Serious adverse events and drug-related adverse events occurred infrequently during both the double-blind (2.2% and 5.6%, respectively) and open-label (14.8% and 6.8%, respectively) portions of the study. Valsartan treatment had no demonstrable negative effects on growth and development. In this study, the first trial of an antihypertensive agent conducted in children <6 years of age, valsartan effectively lowered SBP and diastolic blood pressure compared with placebo.Keywords
This publication has 18 references indexed in Scilit:
- Pharmacologic treatment of hypertension in children and adolescentsThe Journal of Pediatrics, 2006
- Clinical Experience With Angiotensin Receptor Blockers With Particular Reference to ValsartanThe Journal of Clinical Hypertension, 2004
- Successes and shortcomings of the Food and Drug Modernization Act.American Journal of Hypertension, 2003
- Oral antihypertensive trial design and analysis under the pediatric exclusivity provisionAmerican Heart Journal, 2002
- ValsartanDrugs, 1997
- Hypertension in ChildrenNew England Journal of Medicine, 1996
- Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: A comparative study of the efficacy and safety against amlodipine*Clinical Pharmacology & Therapeutics, 1996
- Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared with placebo and enalaprilJournal Of Hypertension, 1996
- Etiology of sustained hypertension in children in the Southwestern United StatesPediatric Nephrology, 1994
- The Use of Plasma Creatinine Concentration for Estimating Glomerular Filtration Rate in Infants, Children, and AdolescentsPediatric Clinics of North America, 1987